Cancer Institute A national cancer institute
designated cancer center

Beverly S. Mitchell, M.D.

Publication Details

  • Purinogenic immunodeficiency diseases: selective toxicity of deoxyribonucleosides for T cells.

    Mitchell BS, Mejias E, Daddona PE, Kelley WN. Proc Natl Acad Sci U S A. 1978; 75 (10): 5011-4

    Deoxyadenosine at low concentrations and in the presence of an inhibitor of adenosine deaminase (adenosine aminohydrolase, EC 3.5.4.4) is markedly toxic to lymphoblast cell lines of T cell origin but does not impair growth of B cell lines. Deoxyguanosine is also more toxic for T lymphoblasts. In the presence of deoxyadenosine or deoxyguanosine, elevation of the corresponding deoxyribonucleoside triphosphate (dATP or dGTP) occurs in T cell, but not in B cell, lines. The addition of deoxycytidine or dipyridamole results in lower dATP and dGTP levels and prevents deoxyribonucleoside toxicity. These findings provide a molecular basis for the immunodeficiency observed in individuals with several inborn errors of purine metabolism.

    PubMedID: 311004

Stanford Medicine Resources:

Footer Links: